Kiniksa Pharmaceuticals
KNSA
54 hedge funds and large institutions have $132M invested in Kiniksa Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 10 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
5.84% less ownership
Funds ownership: 86.89% → 81.05% (-5.8%)
11% less funds holding
Funds holding: 61 → 54 (-7)
41% less capital invested
Capital invested by funds: $224M → $132M (-$91.4M)
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.89M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$1.75M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.66M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.59M |
| 3 |
First Manhattan
New York
|
-$866K |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$866K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$849K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
51
Cubist Systematic Strategies
Stamford,
Connecticut
| $3K | -$3.96K | -358 | -51% |
|
52
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
53
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
VC
54
Vivo Capital
Palo Alto,
California
| – | -$11.4M | -843,478 | Closed |
|
|
55
Fidelity Investments
Boston,
Massachusetts
| – | -$8.59M | -634,539 | Closed |
|
|
56
First Manhattan
New York
| – | -$866K | -63,976 | Closed |
|
|
FCMI
57
Foresite Capital Management IV
Larkspur,
California
| – | -$866K | -63,922 | Closed |
|
|
EAM
58
Eventide Asset Management
Boston,
Massachusetts
| – | -$512K | -37,807 | Closed |
|
59
D.E. Shaw & Co
New York
| – | -$354K | -26,134 | Closed |
|
|
SIM
60
Spark Investment Management
New York
| – | -$281K | -20,800 | Closed |
|
61
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$234K | -17,300 | Closed |
|
|
PCM
62
Prelude Capital Management
New York
| – | -$6K | -425 | Closed |
|
|
CWA
63
Clarus Wealth Advisors
Peoria,
Arizona
| – | -$3K | -226 | Closed |
|
|
TRCT
64
Tower Research Capital (TRC)
New York
| – | +$331 | +30 | New |
|
KNSA Hedge Fund Activity: Q3 2019 in Review
54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2019, worth a combined $132M — down 41% from $224M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KNSA and 3 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 25 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $2.89M. The largest seller was Vivo Capital, exiting entirely with an estimated $11.4M sold.
- 54 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2019, down from 61 in Q2 2019.
- Funds reported $132M of Kiniksa Pharmaceuticals stock for Q3 2019, down 41% quarter-over-quarter.
- 3 funds opened new Kiniksa Pharmaceuticals positions in Q3 2019 and 10 closed out, a net change of -7 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2019 was ArrowMark Colorado Holdings, an estimated $2.89M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $11.4M sold.
Based on aggregated 13F filings for Q3 2019.